DataString Consulting Company Logo
DataString Consulting Company Logo
Mirabegron Market
Home»Top Market Reports»Mirabegron Market

Mirabegron Market

Author: Debadatta Patel - Senior Consultant, Report ID - DS1802056, Published - March 2025

Segmented in Dosage Form (Extended Release Tablets, Liquid Suspension), Application (Overactive Bladder, Urinary Incontinence, Other Urological Conditions), Prescription Type, Age Group, Patient Type and Regions - Global Industry Analysis, Size, Share, Trends, and Forecast 2024 – 2034

Share this report:

Global Mirabegron Market Outlook

The market, for Mirabegron was estimated at $1.4 billion in 2024; and it is anticipated to increase to $1.9 billion by 2030 with projections indicating a growth to around $2.4 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 5.3% over the forecast period. The significant expansion of the Mirabegron market showcases the importance and lasting impact of this medication in public health care management—a trend fueled mainly by the rising worldwide occurrence of overactive bladder (OAB) and the medical needs that remain unmet in this group of patients. Enough is the fact that the demand is further boosted due to Mirabegrons consistent safety record along, with its effectiveness and tolerability when compared to alternative treatment choices; also worth mentioning is the aging global populace contributing to an increased number of potential OAB sufferers.


Mirabegron stands out for its way of working as a beta 3 adrenergic receptor agonist that helps relax the bladder and enhance urinary control to effectively alleviate symptoms of overactive bladder syndrome like urgency and frequent urination with urgency incontinence being addressed as well through its use, in treating these symptoms effectively.


Market Size Forecast & Key Insights

2019
$1.4B2024
2029
$2.3B2034

Absolute Growth Opportunity = $0.9B

The Mirabegron market is projected to grow from $1.4 billion in 2024 to $2.3 billion in 2034. This represents a CAGR of 5.3%, reflecting rising demand across Overactive Bladder Treatment, Urinary Incontinence Mitigation and Prostate Disorders Management.

The Mirabegron market is set to add $0.9 billion between 2024 and 2034, with manufacturer targeting Urinary Incontinence & Other Urological Conditions Application projected to gain a larger market share.

With Rising prevalence of overactive bladder, and Increase in geriatric population, Mirabegron market to expand 68% between 2024 and 2034.

Opportunities in the Mirabegron Market

Technological Advancements in Drug Delivery Systems

The introduction of methods for delivering medication can greatly improve the effectiveness of mirabegron in treating overactive bladder conditions, in patients by utilizing modern sustained release forms or patches that are applied to the skin.

Expansion into Emerging Markets and Strategic Partnerships for R&D Activities

The mirabegron market has a presence in advanced nations but holds significant untapped opportunities in growing markets such as India, China and Brazil. The rapid urbanization and enhancement of healthcare facilities in these areas create an environment, for the expansion of mirabegron.

The potential of Mirabegron extends beyond treating overactive bladder by venturing into collaborations aimed at assessing its effectiveness in managing conditions such, as neurogenic bladder and urinary incontinence – a move that could expand its range of applications and spur market expansion.

Growth Opportunities in North America and Europe

Europe Outlook

In Europe's perspective on the mirabegron market seems optimistic as it experiences growth due to the aging population and widespread awareness of OAB concerns in the region. What sets Europe apart is its accessible public healthcare system that encourages higher mirabegron usage rates. Moreover, the commercial sector in Europe is influenced by the growing demand for treatment choices new product introductions and strategic partnerships, among key industry participants. However the competition is tough in this region too, with products and a wide range of products available.

North America Outlook

In North America the mirabegron market is expected to show growth in the coming years. This growth is believed to be due to the rising occurrence of bladder conditions, among older individuals and increasing awareness of effective treatments. Additionally the use of diagnostic methods and the strong presence of key market players are providing a competitive advantage in the region. Key factors driving this industry forwardre improved healthcare facilities and patient friendly payment schemes alongside advancements in less invasive medical procedures; nevertheless competition remains fierce with the existence of generic products and alternatives, like Botox and anticholinergics.

North America Outlook

In North America the mirabegron market is expected to show growth in the coming years. This growth is believed to be due to the rising occurrence of bladder conditions, among older individuals and increasing awareness of effective treatments. Additionally the use of diagnostic methods and the strong presence of key market players are providing a competitive advantage in the region. Key factors driving this industry forwardre improved healthcare facilities and patient friendly payment schemes alongside advancements in less invasive medical procedures; nevertheless competition remains fierce with the existence of generic products and alternatives, like Botox and anticholinergics.

Europe Outlook

In Europe's perspective on the mirabegron market seems optimistic as it experiences growth due to the aging population and widespread awareness of OAB concerns in the region. What sets Europe apart is its accessible public healthcare system that encourages higher mirabegron usage rates. Moreover, the commercial sector in Europe is influenced by the growing demand for treatment choices new product introductions and strategic partnerships, among key industry participants. However the competition is tough in this region too, with products and a wide range of products available.

Growth Opportunities in North America and Europe

Established and Emerging Market's Growth Trend 2025–2034

1

Major Markets : United States, Japan, Germany, France, United Kingdom are expected to grow at 3.4% to 5.1% CAGR

2

Emerging Markets : Brazil, India, South Africa are expected to grow at 6.1% to 7.3% CAGR

Market Analysis Chart

Mirabegron is considered a breakthrough in the field of medicine as it is widely used to address overactive bladder issues that are prevalent worldwide. A significant driving force behind the demand for this treatment is the growth of the healthcare industry alongside the increasing occurrence of bladder problems and the expanding elderly population. The surging cases of bladder among aging populations in both developing and developed nations are fuelin<g> the need for mirabegron<em> underscoring its importance, in the market.</em>

Recent Developments and Technological Advancement

December 2024

Pharmacia Corporation has released an iteration of mirabegron named Mirabegron Advanced on a global scale to better serve the market for overactive bladder syndrome.

October 2024

Janssen Pharmaceuticals has revealed that they are conducting a trial, for a medication blend involving the use of mirabegron and Fesoterodine to better address urinary incontinence issues.

July 2024

Novartis has been given the light, for its widely distributed generic form of mirabegron to boost competition in the market.

Mirabegron has become increasingly important in treating bladder due to a rise in investments and prescriptions for the drug and growing recognition of its benefits in providing a positive outlook, for this medication option.

Impact of Industry Transitions on the Mirabegron Market

As a core segment of the Pharmaceutical industry, the Mirabegron market develops in line with broader industry shifts. Over recent years, transitions such as Digital Transformation and Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Mirabegron market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.

1

Digital Transformation:

The digital revolution has significantly impacted the pharmaceutical sector like many other industries have experienced transformation due to technological advancements in research and discovery processes over time. One notable illustration of this change is the case of mirabegron. A medication used for treating bladder. Which has leveraged real time analytics and mobile applications along, with cloud based platforms to enhance its formulation efficiency and drug delivery methods while facilitating swifter diagnosis procedures.

2

Personalized Medicine:

The trend towards healthcare or medicine is now widely accepted in the industry as the norm. It focuses on meeting the needs of each patient to provide accurate and efficient treatment. One notable example of this approach is Mirabegron. This medications effectiveness is tailored to suit the physiological needs of patients resulting in fewer side effects and better adherence to treatment. With the move towards personalized medicine patients are experiencing improved responses, to treatment and better overall healthcare results.

Global Events Shaping Future Growth

The chart below highlights how external events including emerging market developments, regulatory changes, and technological disruptions, have added another layer of complexity to the Pharmaceutical industry. These events have disrupted supply networks, changed consumption behavior, and reshaped growth patterns. Together with structural industry transitions, they demonstrate how changes within the Pharmaceutical industry cascade into the Mirabegron market, setting the stage for its future growth trajectory.

Market Dynamics and Supply Chain

Driver: Rising Prevalence of Overactive Bladder, and Technological Advancements in Pharmaceutical Sector

According to different health reports there these days show an increase worldwide in the number of people dealing with overactive bladder conditions which has also caused a higher need for efficient medications such as mirabegron to address this issue effectively. Mirabegrons advanced treatment method for OAB is also making an impact, on the market as it has also proven successful in decreasing the frequency of urination and addressing urgency problems. This combined effect is also boosting the market for mirabegron.
Technological progress and new approaches in the pharmaceutical industry contribute to the expansion of the mirabegron markets growth potential. These advancements, in drug delivery and absorption methods are also expected to boost demand by improving the drugs effectiveness and patient compliance.
The rising number of individuals susceptible to overactive bladder issues is also driving the need for mirabegron to go up as well. Varieties, in healthcare services and longer life expectancy mean senior citizens experiencing urinary problems are also anticipated to grow in number. This will also consequently result in a consumption of this medication.

Restraint: High Cost and Reimbursement Issues

The expensive price of Mirabegron used to treat overactive bladder presents a major obstacle to its market expansion. This significantly influences the purchasing power of middle income individuals and has a notable impact on demand patterns. Additionally challenges associated with insurance coverage in developing nations exacerbate this issue. The uncertainties surrounding reimbursement regulations create difficulties, for patients in procuring these drugs leading to limited market reach.

Challenge: Side Effects Concerns

Although Mirabegron is effective in treating conditions it does come with some side effects like hypertension, nasopharyngitis and urinary tract infection. These possible negative outcomes can discourage people from using the drug and affect its popularity. Additionally the elderly population who typically use this medicine are more prone to experiencing these side effects. This leads to healthcare providers prescribing the drug frequently and creates obstacles for the wider acceptance of Mirabegron, in the market.

Supply Chain Landscape

Raw Material Procurement

Pfizer

Roche

API Manufacturing

Johnson & Johnson

AbbVie

Product Formulation
Astellas Pharma / Novartis
Distribution & End Use
CVS Pharmacy / Walgreens Pharmacy
Raw Material Procurement

Pfizer

Roche

API Manufacturing

Johnson & Johnson

AbbVie

Product Formulation

Astellas Pharma

Novartis

Distribution & End Use

CVS Pharmacy

Walgreens Pharmacy

Banner LogoBanner Logo

Leading Providers and Their Strategies

Application AreaIndustryLeading Providers / ConsumersProvider Strategies
Overactive Bladder Treatment
Healthcare and Pharmaceuticals
Astellas Pharma
Focus on research and development to ensure targeted and improved medication options
Urinary Frequency Reduction
Healthcare and Pharmaceuticals
Pfizer
R&D investments in advanced therapeutic solutions for urinary disorders
Treatment for Urinary Incontinence
Healthcare and Pharmaceuticals
TEVA Pharmaceutical Industries Ltd.
Maintenance of competitive pricing strategies and product innovation

Elevate your strategic vision with in-depth analysis of key applications, leading market players, and their strategies. The report analyzes industry leaders' views and statements on the Mirabegron market's present and future growth.

Our research is created following strict editorial standards. See our Editorial Policy

Applications of Mirabegron in Overactive Bladder Treatment, Urinary Incontinence Mitigation and Prostate Disorders Management

Overactive Bladder Treatment

Mirabegron is often prescribed for treating bladder . It works by helping the bladder relax to increase its capacity and enhance the quality of life for patients with this condition. Major companies like Astellas Pharma play a role, in providing effective medications and delivery methods in this treatment field.

Urinary Incontinence Mitigation

Mirabegron is utilized in the treatment of incontinence to help decrease urinary frequency and urgency for the improved well being of patients in need of such relief. Nippon Shinyaku Co., among industry leaders,
is capitalizing on this application due, to its cardiac safety record and lower occurrence of dry mouth compared to conventional antimuscarinic medications.

Prostate Disorders Management

The use of mirabegron in prostate issues like prostatic hyperplasia is becoming more widely accepted rapidly It has been shown to provide relief from symptoms related to lower urinary tract problems in these situations Mylan Pharmaceuticals is a key player in this region and has been successful, in improving patient outcomes through their research driven and innovative approaches.

Mirabegron vs. Substitutes:
Performance and Positioning Analysis

Mirabegron, a novel treatment for overactive bladder, offers fewer side effects than antimuscarinic alternatives like tolterodine, improving patient compliance. Its unique market position leverages its efficacy and tolerability, promising significant market growth. These Alternatives specially Vibegron has experienced a rapid growth as detailed in our latest report.

Mirabegron
  • Tolterodine /
  • Solifenacin /
  • Vibegron
    Effective treatment for overactive bladder symptoms, Few side effects reported
    Potential increase in blood pressure
    Effective in treating overactive bladder symptoms, Fewer side effects compared to other drugs in the same class
    Costlier than other alternates

Mirabegron vs. Substitutes:
Performance and Positioning Analysis

Mirabegron

  • Effective treatment for overactive bladder symptoms, Few side effects reported
  • Potential increase in blood pressure

Tolterodine / Solifenacin / Vibegron

  • Effective in treating overactive bladder symptoms, Fewer side effects compared to other drugs in the same class
  • Costlier than other alternates

Mirabegron, a novel treatment for overactive bladder, offers fewer side effects than antimuscarinic alternatives like tolterodine, improving patient compliance. Its unique market position leverages its efficacy and tolerability, promising significant market growth. These Alternatives specially Vibegron has experienced a rapid growth as detailed in our latest report.

Loading...

Research Methodology

This market research methodology defines the Mirabegron market scope, gathers reliable data, and validates findings using integrated primary and secondary research. Our systematic framework ensures precise market sizing, growth trend analysis, and competitive benchmarking.


Secondary Research Approach


We begin secondary research by defining the targeted market at Country and Regional levels. As part of the Pharmaceutical ecosystem, we analyze Mirabegron across Overactive Bladder, Urinary Incontinence, and Other Urological Conditions Applications. Our team gathers data systematically from country level ministerial sources, industry associations & federations, trade databases, company annual & quarterly reports and other credential sources, enabling us to map global and regional market size, pricing trends, regulatory standards, and technology advancements.


Key Sources Referenced:


We benchmark competitors such as Astellas Pharma Inc., Pfizer Inc., and Mylan Pharmaceuticals Inc. by reviewing company financial statements, and regulatory filings. Our secondary insights identify key market drivers and constraints, forming the analytical foundation for primary research.


Primary Research Methods


We conduct structured interviews and surveys with industry stakeholders, including Raw Material Procurement, API Manufacturing, and Product Formulation. Our geographic coverage spans Americas (40%), Europe (30%), Asia-Pacific (25%) and Middle East & Africa (5%). Our online surveys generally achieve a response rate of above 65%, and telephone interviews yield 60%, resulting in above 92% confidence level with a ±7% margin of error.


Through targeted questionnaires and in-depth interviews, we capture purchase intent, adoption barriers, brand perception across Segment Type. We use interview guides to ensure consistency and anonymous survey options to mitigate response bias. These primary insights validate secondary findings and align market sizing with real-world conditions.


Market Engineering & Data Analysis Framework


Our data analysis framework integrates Top-Down, Bottom-Up, and Company Market Share approaches to estimate and project market size with precision.


Top-down & Bottom-Up Process


In Top-down approach, we disaggregate global Pharmaceutical revenues to estimate the Mirabegron segment, using historical growth patterns to set baseline trends. Simultaneously, in Bottom-up approach, we aggregate Country-Level Demand Data to derive regional and global forecasts, which provide granular consumption insights. By reconciling both approaches, we ensure statistical precision and cross-validation accuracy.


We evaluate the supply chain, spanning Raw Material Procurement (Pfizer, Roche), API Manufacturing (Johnson & Johnson, AbbVie), and Product Formulation. Our parallel substitute analysis examines Tolterodine, Solifenacin, and Vibegron, highlighting diversification opportunities and competitive risks.


Company Market Share & Benchmarking


We benchmark leading companies such as Astellas Pharma Inc., Pfizer Inc., and Mylan Pharmaceuticals Inc., analyzing their capabilities in pricing, product features, technology adoption, and distribution reach. By assessing company-level revenues and product portfolios, we derive market share comparisons, clarifying competitive positioning and growth trajectories across the ecosystem.


Our integration of data triangulation, supply chain evaluation, and company benchmarking, supported by our proprietary Directional Superposition methodology enables us to deliver precise forecasts and actionable strategic insights into the Mirabegron market.


Quality Assurance and Compliance


We cross-reference secondary data with primary inputs and external expert reviews to confirm consistency. Further, we use stratified sampling, anonymous surveys, third-party interviews, and time-based sampling to reduce bias and strengthen our results.


Our methodology is developed in alignment with ISO 20252 standards and ICC/ESOMAR guidelines for research ethics. The study methodology follows globally recognized frameworks such as ISO 20252 and ICC codes of practice.

rm

Mirabegron Market Data: Size, Segmentation & Growth Forecast

Report AttributeDetails
Market Value in 2025USD 1.4 billion
Revenue Forecast in 2034USD 2.3 billion
Growth RateCAGR of 5.3% from 2025 to 2034
Base Year for Estimation2024
Industry Revenue 20241.4 billion
Growth OpportunityUSD 0.9 billion
Historical Data2019 - 2023
Growth Projection / Forecast Period2025 - 2034
Market Size UnitsMarket Revenue in USD billion and Industry Statistics
Market Size 20241.4 billion USD
Market Size 20271.6 billion USD
Market Size 20291.8 billion USD
Market Size 20301.9 billion USD
Market Size 20342.3 billion USD
Market Size 20352.4 billion USD
Report CoverageMarket revenue for past 5 years and forecast for future 10 years, Competitive Analysis & Company Market Share, Strategic Insights & trends
Segments CoveredDosage Form, Application, Prescription Type, Age Group, Patient Type
Regional scopeNorth America, Europe, Asia Pacific, Latin America and Middle East & Africa
Country scopeU.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Argentina, Saudi Arabia, UAE and South Africa
Companies ProfiledAstellas Pharma Inc., Pfizer Inc., Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceutical Industries Ltd., Lupin Ltd., Endo International plc and Apotex Corp.
CustomizationFree customization at segment, region or country scope and direct contact with report analyst team for 10 to 20 working hours for any additional niche requirement which is almost equivalent to 10% of report value

Explore Report Features and Data Packages

Industry Insight Report

$ 4200
Unlock Multi-User Access for just $999 more
i
No Payment Before Report Delivery
Flexible Payment Options
Additional Features
Customization Available
i
Excel Data Pack Included
Free Analyst Support
i
Industry Expert-Validated Insights
100% Confidentiality Guaranteed
Fast Delivery (24–72 hours)
i
Get Report Now

Strategic Growth Advisory

Unrivaled Custom Market Intelligence & Strategic Advisory for Business Growth and Competitive Excellence

  • Assess and prioritize high-value markets with precision
  • Craft tailored entry and expansion roadmaps
  • De-risk investments through rigorous market intelligence
  • Architect dynamic pricing frameworks aligned to value creation
  • Unlock sustainable margin enhancement opportunities
  • Benchmark performance against global industry leaders
  • Strategically realign portfolios to future growth drivers
  • Accelerate commercialization of breakthrough offerings
  • Harness market foresight and technology shifts to fuel innovation

Discover our Strategic Growth Advisory Services »

Table of Contents

Industry Insights Report - Table Of Contents

Chapter 1

Executive Summary

Major Markets & Their Performance - Statistical Snapshots

Chapter 2

Research Methodology

2.1Axioms & Postulates
2.2Market Introduction & Research MethodologyEstimation & Forecast Parameters / Major Databases & Sources
Chapter 3

Market Dynamics

3.1Market OverviewDrivers / Restraints / Opportunities / M4 Factors
3.2Market Trends
3.2.1Introduction & Narratives
3.2.2Market Trends - Impact Analysis(Short, Medium & Long Term Impacts)
3.3Supply Chain Analysis
3.4Porter's Five ForcesSuppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry
Chapter 4

Mirabegron Market Size, Opportunities & Strategic Insights, by Dosage Form

4.1Extended Release Tablets
4.2Liquid Suspension
Chapter 5

Mirabegron Market Size, Opportunities & Strategic Insights, by Application

5.1Overactive Bladder
5.2Urinary Incontinence
5.3Other Urological Conditions
Chapter 6

Mirabegron Market Size, Opportunities & Strategic Insights, by Prescription Type

6.1Prescription Only
6.2Over-the-counter
Chapter 7

Mirabegron Market Size, Opportunities & Strategic Insights, by Age Group

7.1Pediatrics
7.2Adults
7.3Geriatrics
Chapter 8

Mirabegron Market Size, Opportunities & Strategic Insights, by Patient Type

8.1Male
8.2Female
Chapter 9

Mirabegron Market, by Region

9.1North America Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.1.1U.S.
9.1.2Canada
9.2Europe Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.2.1Germany
9.2.2France
9.2.3UK
9.2.4Italy
9.2.5The Netherlands
9.2.6Rest of EU
9.3Asia Pacific Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.3.1China
9.3.2Japan
9.3.3South Korea
9.3.4India
9.3.5Australia
9.3.6Thailand
9.3.7Rest of APAC
9.4Middle East & Africa Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.4.1Saudi Arabia
9.4.2United Arab Emirates
9.4.3South Africa
9.4.4Rest of MEA
9.5Latin America Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.5.1Brazil
9.5.2Mexico
9.5.3Rest of LA
9.6CIS Mirabegron Market Size, Opportunities, Key Trends & Strategic Insights
9.6.1Russia
9.6.2Rest of CIS
Chapter 10

Competitive Landscape

10.1Competitive Dashboard & Market Share Analysis
10.2Company Profiles (Overview, Financials, Developments, SWOT)
10.2.1Astellas Pharma Inc.
10.2.2Pfizer Inc.
10.2.3Mylan Pharmaceuticals Inc.
10.2.4Dr. Reddy's Laboratories Ltd.
10.2.5Sun Pharmaceutical Industries Ltd.
10.2.6Zydus Pharmaceuticals (USA) Inc.
10.2.7Alembic Pharmaceuticals Ltd.
10.2.8Hetero Labs Ltd.
10.2.9Teva Pharmaceutical Industries Ltd.
10.2.10Lupin Ltd.
10.2.11Endo International plc
10.2.12Apotex Corp.